{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:36:20Z","timestamp":1785447380828,"version":"3.56.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Fondation Saint-Luc, Belgium"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) is widely treated using large radiotherapy margins, resulting in substantial irradiation of the surrounding cerebral structures. In this context, the question arises whether these margins could be safely reduced. In 2018, clinical target volume (CTV) expansion was reduced in our institution from 20 to 15 mm around the gross target volume (GTV) (ie, the contrast-enhancing tumor\/cavity). We sought to retrospectively analyze the impact of this reduction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All adult patients with GBM treated between January 2015 and December 2020 with concurrent chemoradiation (60Gy\/2Gy or 59.4Gy\/1.8Gy) were analyzed. Patients treated using a 20 (CTV20, n\u2005=\u200557) or 15 mm (CTV15, n\u2005=\u200556) CTV margin were compared for target volumes, dose parameters to the surrounding organs, pattern of recurrence, and survival outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mean GTV was similar in both groups (ie, CTV20: 39.7cm3; CTV15: 37.8cm3; P\u2005=\u2005.71). Mean CTV and PTV were reduced from 238.9cm3 to 176.7cm3 (P\u2005=\u2005.001) and from 292.6cm3 to 217.0cm3 (P\u2005&amp;lt;\u2005.001), for CTV20 and CTV15, respectively. As a result, average brain mean dose (Dmean) was reduced from 25.2Gy to 21.0Gy (P\u2005=\u2005.002). Significantly lower values were also observed for left hippocampus Dmean, brainstem D0.03cc, cochleas Dmean, and pituitary Dmean. Pattern of recurrence was similar, as well as patient outcome, ie, median progression-free survival was 8.0 and 7.0 months (P\u2005=\u2005.80), and median overall survival was 11.0 and 14.0 months (P\u2005=\u2005.61) for CTV20 and CTV15, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In GBM patients treated with chemoradiation, reducing the CTV margin from 20 to 15 mm appears to be safe and offers the potential for less treatment toxicity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npad071","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T17:29:42Z","timestamp":1698427782000},"page":"249-254","source":"Crossref","is-referenced-by-count":3,"title":["Impact of clinical target volume margin reduction in glioblastoma patients treated with concurrent chemoradiation"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7997-3865","authenticated-orcid":false,"given":"Dario","family":"Di Perri","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Cliniques Universitaires Saint-Luc , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hofstede","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"Hartgerink","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Terhaag","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud","family":"Houben","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida A","family":"Postma","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, MHeNs School for Mental Health and Neuroscience , Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hoeben","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center+ , Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Anten","sequence":"additional","affiliation":[{"name":"Department of Neurology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ackermans","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Maastricht University Medical Centre+, Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Compter","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00eblle B P","family":"Eekers","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"issue":"2","key":"2024051013153026600_CIT0001","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/neuonc\/noz203","article-title":"Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015","volume":"22","author":"Davis","year":"2020","journal-title":"Neuro Oncol."},{"issue":"3","key":"2024051013153026600_CIT0002","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"5","key":"2024051013153026600_CIT0003","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.prro.2015.12.002","article-title":"Glioblastoma: Radiation treatment margins, how small is large enough","volume":"6","author":"Wernicke","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"2024051013153026600_CIT0004","doi-asserted-by":"crossref","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol."},{"issue":"1","key":"2024051013153026600_CIT0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.radonc.2015.12.003","article-title":"ESTRO-ACROP guideline \u201ctarget delineation of glioblastomas\u201d","volume":"118","author":"Niyazi","year":"2016","journal-title":"Radiother Oncol."},{"issue":"1","key":"2024051013153026600_CIT0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11060-019-03152-9","article-title":"NRG brain tumor specialists consensus guidelines for glioblastoma contouring","volume":"143","author":"Kruser","year":"2019","journal-title":"J Neurooncol."},{"issue":"3","key":"2024051013153026600_CIT0007","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2010.08.020","article-title":"Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide","volume":"97","author":"Minniti","year":"2010","journal-title":"Radiother Oncol."},{"key":"2024051013153026600_CIT0008","doi-asserted-by":"crossref","first-page":"109435","DOI":"10.1016\/j.radonc.2022.11.024","article-title":"Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis","volume":"181","author":"Minniti","year":"2023","journal-title":"Radiother Oncol."},{"issue":"1","key":"2024051013153026600_CIT0009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2017.12.013","article-title":"The EPTN consensus-based atlas for CT- and MR-based contouring in neuro-oncology","volume":"128","author":"Eekers","year":"2018","journal-title":"Radiother Oncol."},{"key":"2024051013153026600_CIT0010","article-title":"EPTN international neurological contouring atlas","author":"Eekers","year":"2017","journal-title":"Cancer Data"},{"issue":"11","key":"2024051013153026600_CIT0011","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol."},{"issue":"9","key":"2024051013153026600_CIT0012","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1080\/15548627.2020.1816343","article-title":"Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: A phase IB trial","volume":"17","author":"Compter","year":"2021","journal-title":"Autophagy"},{"key":"2024051013153026600_CIT0013","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1748-717X-9-130","article-title":"Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide","volume":"9","author":"Gebhardt","year":"2014","journal-title":"Radiat Oncol."},{"issue":"1","key":"2024051013153026600_CIT0014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.prro.2018.06.001","article-title":"Using smaller-than-standard radiation treatment margins does not change survival outcomes in patients with high-grade gliomas","volume":"9","author":"Guram","year":"2019","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"2024051013153026600_CIT0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijrobp.2009.10.048","article-title":"Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma","volume":"79","author":"McDonald","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2024051013153026600_CIT0016","first-page":"86","article-title":"Impact of volume of irradiation on survival and quality of life in glioblastoma: A prospective, phase 2, randomized comparison of RTOG and MDACC protocols","volume":"7","author":"Kumar","year":"2020","journal-title":"Neurooncol Pract"},{"key":"2024051013153026600_CIT0017","first-page":"14","article-title":"Morphological changes after cranial fractionated photon radiotherapy: Localized loss of white matter and grey matter volume with increasing dose","volume":"31","author":"Nagtegaal","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"2024051013153026600_CIT0018","first-page":"99","article-title":"Time- and dose-dependent volume decreases in subcortical grey matter structures of glioma patients after radio(chemo)therapy","volume":"36","author":"Raschke","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"2024051013153026600_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2020.03.023","article-title":"Cognitive impairment following radiation to hippocampus and other brain structures in adults with primary brain tumours","volume":"148","author":"Haldbo-Classen","year":"2020","journal-title":"Radiother Oncol."},{"key":"2024051013153026600_CIT0020","first-page":"86","article-title":"Associations between patient-reported outcomes and radiation dose in patients treated with radiation therapy for primary brain tumours","volume":"31","author":"Haldbo-Classen","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"2024051013153026600_CIT0021","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijrobp.2020.10.002","article-title":"Quantitating interfraction target dynamics during concurrent chemoradiation for glioblastoma: A prospective serial imaging study","volume":"109","author":"Stewart","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2024051013153026600_CIT0022","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13014-022-02007-4","article-title":"A prospective comparison of adaptive and fixed boost plans in radiotherapy for glioblastoma","volume":"17","author":"Matsuyama","year":"2022","journal-title":"Radiat Oncol."},{"issue":"1","key":"2024051013153026600_CIT0023","doi-asserted-by":"crossref","first-page":"E617","DOI":"10.1016\/j.ijrobp.2019.06.1148","article-title":"A multi-institutional estimation of interobserver variability in glioblastoma delineation in the EORTC-1709-BTG\/CCTG CE 8 Trial","volume":"105","author":"Kaidar-Person","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npad071\/53253456\/npad071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/11\/3\/249\/57502660\/npad071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/11\/3\/249\/57502660\/npad071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T13:15:53Z","timestamp":1715346953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/11\/3\/249\/7331123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,10,27]]},"published-print":{"date-parts":[[2024,5,10]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npad071","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2023,10,27]]}}}